QDEL — QuidelOrtho Corporation

QDEL (QuidelOrtho) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Revenue: $700 million, down 4% year-over-year from $727 million, primarily due to lower COVID and donor screening revenue.
• Organic Sales Growth: 5% excluding COVID and U.S. donor screening business.
• Adjusted EBITDA: $177 million, representing a 25% margin, a 180 basis point improvement year-over-year.
• Adjusted Diluted EPS: $0.80, a 36% increase year-to-date to $1.66.
• Cash Position: $98 million in cash, with $100 million drawn from a $700 million credit facility.
• Net Debt to Adjusted EBITDA Ratio: 4.4x, slightly above target due to cash flow impacts from ERP system conversion.

2. Strategic Updates and Business Highlights:

• Business Performance: Growth driven by Labs (4%), Immunohematology (5%), and Point-of-Care (7%) segments. International markets, especially Latin America, showed strong growth (21% overall).
• Cost Savings Initiatives: Over $140 million in cost savings achieved, contributing to improved margins.
• R&D Developments: Clearance of a new high-sensitivity troponin assay for the VITROS platform, enhancing the cardiac panel's competitiveness.
• Operational Improvements: Focus on reducing procurement costs and optimizing supply chains to offset tariff impacts.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: Narrowed to between $2.68 billion and $2.74 billion, with neutral FX impact expected.
• Adjusted EBITDA Guidance: Revised to $585 million to $605 million, maintaining a 22% margin.
• Adjusted Diluted EPS Guidance: Updated to $2.00 to $2.15, reflecting higher interest expenses and taxes.
• Future Growth: Anticipated FDA clearance for LEX Diagnostics by late 2025 or early 2026, with a gradual rollout expected.

4. Bad News, Challenges, or Points of Concern:

• Declining Revenue: Significant declines in COVID-related revenue (63%) and U.S. donor screening (48%).
• Goodwill Impairment: A $701 million goodwill impairment charge recorded due to stock price performance and market cap concerns.
• Cash Flow Issues: Adjusted free cash flow was negative $50 million due to timing of accounts receivable and payable related to the ERP conversion.
• Competitive Pressures: Ongoing impacts from Value-Based Purchasing (VBP) and new procurement policies in China affecting growth expectations.

5. Notable Q&A Insights:

• Competitive Wins: CEO Brian Blaser highlighted successful wins across various geographies, emphasizing a focus on profitable contracts.
• Immunohematology Growth: While Q3 showed 5% growth, it was noted that full-year growth might settle around 3-4%.
• LEX Diagnostics: Expected to have a dilutive impact on margins initially, with significant revenue scaling anticipated by 2027 or 2028.
• Sofia Franchise: The installed base remains stable, with expectations for continued strong performance in the upcoming respiratory season.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A, providing a comprehensive overview of QuidelOrtho's performance and outlook for Q3 2025.